Journal article
Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis
EP Kusnadi, AS Trigos, C Cullinane, DL Goode, O Larsson, JR Devlin, KT Chan, DP De Souza, MJ McConville, GA McArthur, G Thomas, E Sanij, G Poortinga, RD Hannan, KM Hannan, J Kang, RB Pearson
bioRxiv | Cold Spring Harbor Laboratory | Published : 2019
DOI: 10.1101/847723
Abstract
Abstract Elevated ribosome biogenesis in oncogene-driven cancers is commonly targeted by DNA-damaging cytotoxic drugs. Our first-in-human trial of CX-5461, a novel, less genotoxic agent that specifically inhibits ribosome biogenesis via suppression of RNA Polymerase I (Pol I) transcription, revealed single agent efficacy in refractory blood cancers. Despite this clinical response, patients were not cured. In parallel, we demonstrated a marked improvement in the in vivo efficacy of CX-5461 in combination with PI3K/AKT/mTORC1 pathway inhibitors. Here we show that this improved efficacy is associated with specific suppression of translation of mRNAs encoding regulators of cellular metabolism. I..
View full abstract